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provided by nonprofessionals. The costs of indirect care were reported to be consider-
ably higher than the direct costs. Direct annual costs range from 1,869€ for Poland to 
22,230$ for the US. The costs for inpatient care generate the main part of the direct 
economic burden. In the majority of cases the economic impact is referred to the 
severity of the CHF expressed by the New York Heart Association functional clas-
sification (NYHA) stage. The more severe NYHA stages III and IV are associated with 
higher costs. ConClusions: Our review highlights the considerable and growing 
economic burden of CHF on the health care systems of developed countries. The 
COI studies included in this review show large variations in methodology used and 
the cost results vary as a consequence. Further research is needed to highlight the 
economic burden of indirect costs of CHF. High quality data from COI studies with a 
robust methodology applied can inform policy makers about the major cost drivers 
of CHF and can be used as the basis of further economic evaluations.
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objeCtives: Atrial Fibrillation (AF) is the most common sustained cardiac arrhyth-
mia. The increasing prevalence of AF and the advances in the management of the 
disease in recent years highlight the importance of updating cost of illness studies 
to understand both the financial burden and the related health care resource use. 
The main purpose of this study was to perform a cost analysis of AF hospitalized 
cases in a large general population of Italy from the perspective of the Health System 
(HS). Methods: This is an observational retrospective cohort study conducted 
using automatic health care administrative archives of the Italian publicly funded 
HS. The study cohort included all subjects living in Lombardy, a region of Northern 
Italy, with a hospital discharge for AF or flutter (index event) in the time period 1st 
January 2003 - 31st December 2009. A pre-index period of eligibility shorter than 3 
years was an exclusion criterion. Subjects were followed until 31stDecember 2010 or 
death or emigration, collecting data related to hospitalizations, drug prescriptions 
and outpatient visits and related direct costs. Results: The mean age of patients 
admitted to hospital with a diagnosis of AF was 72 years (± 14.1 standard deviation). 
Women were older than men and 50% of patients were male. Major comorbidities 
at index event were: congestive heart failure, cerebrovascular diseases, chronic 
pulmonary diseases and diabetes. The mean cost of index hospitalization was about 
3,600 € (± 3,900 € ). Survival at one year from index event was 83%, 66% at four years 
and 53% at seven years. The main driver of direct medical cost during follow-up 
was inpatient care, followed by drug therapies. ConClusions: AF resulted in a 
substantial medical cost, reflecting resource-intensive and long-term treatments. 
These costs accompanied with increasing prevalence of AF, justify increased atten-
tion to the management of patients with AF.
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objeCtives: Map and cost the patient pathway for acute and chronic heart fail-
ure patients in Ireland. Obtain the key cost parameters using a top down approach, 
whilst highlighting the economic and societal impact of this non communicable 
disease. Methods: A prevalence based top down approach was applied to estimate 
the cost of heart failure in Ireland for the year 2012, taking a societal perspective. 
Data on primary and all case diagnoses were obtained from the National Hospital 
In-Patient Enquiry Scheme (HIPE). Market research identified admissions in private 
hospital. Patients hospitalised with heart failure have been taken as representative 
of patients with Acute Decompensated Heart Failure (ADHF). All treatment pathways 
associated with the direct cost of both prevalent and incident cases of heart failure 
were confirmed and validated by health care professionals in primary and secondary 
care settings. Indirect and economic costs consisted of informal care and Life Years 
Lost (LYL), respectively. These were estimated using national surveys and registries, 
such as the Central Statistics Office (CSO). LYL were monetised using Irish specific 
life tables and the value of a statistical and/or the QALY threshold. Where data were 
lacking or uncertain, treatment algorithms were confirmed and validated through 
scientific engagement with key opinion leaders. Results:  The total cost of heart 
failure in Ireland for the year 2012 was estimated at € 662.3 million. Indirect and eco-
nomic costs were identified as the largest cost component at € 473.7m (76%), while the 
direct cost represented 24% of the cost burden. ConClusions: Once HF has devel-
oped, the pathophysiology of the condition is characterised by high morbidity and 
mortality, frequent hospitalisation, and a large reliance on informal care. This study 
identified large regional variation in available heart failure services, hence impacting 
the necessary follow up care. As a result, a substantial cost driver in the management 
and care of heart failure patients is informal care. This cost has not been considered 
in previous heart failure studies, making it an important area for future research.
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objeCtives: Trauma patients often experience significant hemorrhage and, there-
fore, may require more resources during hospitalization than patients who do not 
hemorrhage. The cost of blood/blood products is poorly understood in trauma patients 
and not well documented in the literature. Our objective was to evaluate the outcomes 
and cost of care for trauma patients based on bleeding status. Methods: Patients 
with costs and length of stay (LOS) greater than zero, discharged between January 1, 
2010 and December 31, 2012, were identified in the Premier Hospital Database based 
on select ICD9 codes. All costs were based on hospital reported costs. Patients who 
received blood products prior to the day of surgery were excluded. Multivariate regres-
had no recurrent CV events was estimated to be £10.4 billion versus £14.94 billion 
with recurring CV events under current SOC. This translated into a 43.8% higher 
economic burden on health care. ConClusions: The subsequent CV events in 
post-MI patients pose an additional economic burden of 44% on UK health care 
despite the current SoC. This indicates the need to design new interventions to 
reduce the risk of further CV events in post-MI patients.
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objeCtives: To estimate the costs of atherosclerotic and haemorrhagic events 
associated with Acute Coronary Syndrome (ACS) treated with ASA + Clopidogrel, 
in Turkish settings. Methods: An expert panel was organized to reflect the solid 
data regarding disease management patterns and options to Turkish payer for 
reimbursement process. Due to the multidisciplinary nature of the ACS, physi-
cians from the cardiology, neurology and cardiovascular surgery participated 
to panel. Cost components of bleeding events, haemorrhagic stroke, ischemic 
stroke, myocardial infarction and revascularization have been identified. Experts 
have reviewed their daily clinical practices and local & global literature for the 
related complications along with medical procedures. All cost components includ-
ing medications, hospitalization, surgical treatments follow up procedures and 
rehabilitation were considered. For the prices of medications, and diagnostic and 
therapeutic procedures, March 2014 local prices have been taken into account. 
For Turkish Lira: Euro conversion, Turkish Central Bank March 2013 currency rate 
(was used TL/Euro = 3.06). Results: The cost of MI in the first year is 2.004€ and 
376€ for the following years. (≈%70) of the cost comes from non-pharmacological 
treatment. Costs of ischemic and hemorrhagic stroke for the acute period and fol-
lowing three months are 2.266 € and 3.010€ , respectively. Annual cost of ischemic 
and haemorrhagic strokes are 2.951€ and 3.646€ for the first year. The main cost 
drivers for stroke are also non-pharmacological treatments, mainly physiotherapy 
for stroke. (≈%70-80 for the 1st year) Coronary revascularization costs 833€ for 
percutaneous interventionand 2.354€ for coronary by-pass. Bleeding costs are 
relatively low compared to other complications. Major and minor bleedings are 
189€ /event and 17€ /event. ConClusions: Costs of the ACS related complications 
are quite high. Especially acute phase of MI and stroke has significant burden of 
the budget. More effective secondary prevention of the ACS might reduce the 
burden of disease in the Turkish settings.
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objeCtives: The aim of this study has been determination of the burden of statins in 
the treatment of acute coronary syndrome (ACS) and angina pectoris (AP). There is a 
significant number of registered statins (brands and generics) in Belarus (lovastatin, 
atorvastatin simvastatin and rosuvastatin). Pharmacoeconomic studies of statins are 
topical because of the competition at the pharmaceutical market to ensure rational 
use of public and private funds. Methods: Overview of available statins has been 
conducted. Equivalent effective doses were established on the basis of the published 
data. “Cost of illness” has been calculated with the help of national clinical guidelines 
for treatment of ACS and AP. Comparison of the each statin burden by determining 
the proportion of funds falling at each one in the overall cost of the patient´s care has 
been made. Results: Cost of statins had no significant value in the overall “cost of 
illness” for acute coronary pathology (ranged from 0.3% to 1.88%). The cost of statins 
has a significant impact on the final “cost of illness” in the case of chronic cardiac 
pathology and ranges from 18.54% to 39.9%. Burden of rosuvastatin (Mertenil) in 
this analysis seems to be the most stable and predictable because of the changes 
in a narrow range (23.9% - 26.48% in the first year and 28.48% - 29.49% - the second 
and subsequent years) vs. atorvastatin (19.35% - 35.7% in the first year and 23.3% - 
39.9% in the second and subsequent years) and simvastatin (18.54% - 32.62% in the 
first year and 22.13% - 35.89% in the second and subsequent years). ConClusions: 
Pharmacoeconomic evaluation of statin choosing is important for prolonged use of 
medicines but not for short-term use in acute coronary syndrome.
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objeCtives: The aim of this study was to perform a systematic review of recently 
published Cost of Illness (COI) studies related to Chronic Heart Failure (CHF) to high-
light the increasing cost impact associated with the disease and identify the major 
cost drivers. Methods: A systematic review was conducted from 2004-2014 to 
identify COI studies related to CHF, searching the PubMed, Science Direct, Cochrane 
Library, Scopus and York CRD databases. The PRISMA guidelines were applied for the 
search. Results: 12 studies were included in this review and were grouped into a 
prevalence- and an incidence-based approach. Most articles were considering only 
the direct medical costs (hospitalization, medication, primary care) of CHF, while 
some of them also assessed the economic impact of indirect care, i.e. informal care 
